| Lee, Mark C |
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color |
|
|
| Active, not recruiting | 3 | 80 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 05/24 | 02/25 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
SCALP1, NCT05910450: A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss |
|
|
| Recruiting | 3 | 726 | US, RoW | Clascoterone 5% solution, CB-03-01 5% solution, Vehicle solution, Vehicle | Cassiopea SpA, Ergomed PLC, Pharmapace Inc, Canfield Scientific Inc., ICON Clinical Research | Alopecia, Androgenetic | 10/24 | 04/25 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight |
|
|
| Recruiting | 3 | 250 | US | Ixekizumab, LY2439821, Tirzepatide, LY3298176 | Eli Lilly and Company | Psoriasis, Obesity | 12/25 | 05/26 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
NCT05772520: The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis |
|
|
| Completed | 2 | 82 | US | TLL018 tablets, TLL018 Placeboes | Hangzhou Highlightll Pharmaceutical Co., Ltd | Plaque Psoriasis | 12/24 | 12/24 | | |
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis |
|
|
| Active, not recruiting | 2 | 236 | Europe, Canada, Japan, US, RoW | LY3454738, Placebo | Eli Lilly and Company | Atopic Dermatitis | 06/25 | 03/26 | | |
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria |
|
|
| Recruiting | 2 | 154 | Europe, Canada, US | Oral EP262, Placebo | Escient Pharmaceuticals, Inc | Chronic Spontaneous Urticaria | 06/25 | 07/25 | | |
IDAML, NCT01518556: Safety and Efficacy Study of Idarubicin Dose Intensification to Treat Acute Myeloid Leukemia |
|
|
| Active, not recruiting | 1/2 | 49 | RoW | Idarubicin, IDARU INJ | Konkuk University Medical Center, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, Seoul National University Hospital, Ewha Womans University, Samsung Medical Center, Chonbuk National University Hospital, Pusan National University Hospital, Hanyang University Seoul Hospital, Soon Chun Hyang University | Leukemia, Myeloid, Acute | 06/24 | 06/25 | | |
NCT06119529: A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis |
|
|
| Terminated | 1 | 18 | US | LY3872386, Prednisone, Placebo | Eli Lilly and Company | Healthy, Atopic Dermatitis | 04/24 | 04/24 | | |
| Active, not recruiting | N/A | 100 | Europe, US | Distal femur plates | AO Innovation Translation Center | Distal Femur Fracture | 06/25 | 06/25 | | |
| Zhang, Yi |
NCT04771689: Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients |
|
|
| Not yet recruiting | 4 | 60 | US | Buprenorphine/Naloxone, Suboxone | Massachusetts General Hospital | Post-operative Pain | 12/22 | 12/22 | | |
| Recruiting | 4 | 20 | RoW | PCSK9 inhibitor （Alirocumab）plus standard medications, standard medications | Shanghai Tong Ren Hospital | Early PCSK9 Inhibitor on Ventricular Remodling | 12/24 | 06/25 | | |
NCT05292404: Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction |
|
|
| Recruiting | 4 | 160 | RoW | alirocumab, conventional treatment | Shanghai Tong Ren Hospital, China Cardiovascular Association | Acute Myocardial Infarction | 06/25 | 12/25 | | |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
NCT06512584: Efficacy and Safety of PJ009 in Patients with Short Bowel Syndrome Requiring Parenteral Nutrition |
|
|
| Recruiting | 3 | 72 | RoW | PJ009, Glucagon-Like Peptide 2 (GLP-2) analogue, PJ009 Placebo, GLP-2 analogue Placebo | Chongqing Peg-Bio Biopharm Co., Ltd. | Short Bowel Syndrome | 03/26 | 04/26 | | |
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
|
|
| Active, not recruiting | 2/3 | 301 | RoW | RC48-ADC, RC48, Lapatinib, Capecitabine | RemeGen Co., Ltd. | Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases | 07/24 | 12/24 | | |
NCT04398940: A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 71 | RoW | TQ-B3139 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 01/22 | 10/22 | | |
NCT06524518: A Multicenter Randomized Controlled Study of Interventional Treatment for Operable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer With Potential Recurrence as Minimal Residual Disease(MRD) Positive |
|
|
| Not yet recruiting | 2 | 213 | RoW | Chemotherapy combined with immunization | Xuanwu Hospital, Beijing | DFS | 07/26 | 12/29 | | |
NCT03634501: Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells |
|
|
| Recruiting | 1/2 | 200 | RoW | Activated NK | Xuanwu Hospital, Beijing | Lung Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer | 09/21 | 09/22 | | |
NCT03638206: Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies |
|
|
| Recruiting | 1/2 | 73 | RoW | CAR-T cell immunotherapy | Shenzhen BinDeBio Ltd., The First Affiliated Hospital of Zhengzhou University | B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma, Hepatoma, Gastric Cancer, Pancreatic Cancer, Mesothelioma, Colorectal Cancer, Esophagus Cancer, Lung Cancer, Glioma, Melanoma, Synovial Sarcoma, Ovarian Cancer, Renal Carcinoma | 03/23 | 03/23 | | |
NCT05117138: Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors |
|
|
| Not yet recruiting | 1/2 | 39 | RoW | AMT-116 CAR-T cells, AMT-253 CAR-T cells | Beijing Immunochina Medical Science & Technology Co., Ltd. | Melanoma, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma | 12/23 | 03/24 | | |
NCT06316791: Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases |
|
|
| Recruiting | 1 | 24 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Lupus Erythematosus, Systemic | 12/24 | 12/25 | | |
NCT05122221: CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers |
|
|
| Recruiting | 1 | 12 | RoW | Fludarabine + Cyclophosphamide, Interleukin-2, CRTE7A2-01 TCR-T Cell | Corregene Biotechnology Co., Ltd | Cervical Cancer, Anal Cancer, Head and Neck Cancers | 03/23 | 12/24 | | |
NCT06152757: BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors |
|
|
| Recruiting | 1 | 14 | RoW | First dose, Second dose, The third dose, The fourth dose | BioSyngen Pte Ltd, The First Affiliated Hospital of Zhengzhou University | Gastrointestinal Tumors | 07/25 | 07/27 | | |
NCT05381181: Safety and Efficacy Evaluation of Next-generation CD19-UCART |
|
|
| Not yet recruiting | 1 | 20 | NA | CD19-UCART | Bioray Laboratories, The First Affiliated Hospital of Zhengzhou University | Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma | 05/24 | 05/26 | | |
NCT06077903: GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | GT101 | Grit Biotechnology | Adult | 07/24 | 07/24 | | |
NCT06515626: Genetically Modified T Cells Treating Malignant Tumors |
|
|
| Recruiting | 1 | 100 | RoW | CAR-T cell reinfusion | Yi Zhang | Solid Tumor | 12/25 | 12/27 | | |
NCT06548620: A Study of RD06-04 in Patients With Active Autoimmune Diseases |
|
|
| Not yet recruiting | 1 | 18 | RoW | RD06-04 cell infusion | Nanjing Bioheng Biotech Co., Ltd. | SLE (Systemic Lupus), Sclerosis, ANCA Associated Vasculitis, IIM, SS, MS, NMO Spectrum Disorder, MG | 08/26 | 08/27 | | |
NCT06671236: Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases |
|
|
| Recruiting | 1 | 12 | US, RoW | Autologous Human Polyclonal Regulatory T Cells Injection (NP001 Cell Injection) | Novabio Therapeutics, The First Affiliated Hospital of Zhengzhou University | Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease(AD), Multiple System Atrophy, MSA | 12/26 | 12/27 | | |
NCT06094426: Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | GT316 | Grit Biotechnology | Solid Tumor, Adult, GT316 | 02/26 | 02/26 | | |
NCT06560580: Ditefossol Sodium 3% Eye Drops in Patients With Dry Eye |
|
|
| Completed | N/A | 97 | RoW | 3% Diquafosol Sodium Eye Drops | Tianjin Eye Hospital | Dry Eye Disease | 07/23 | 07/24 | | |
NCT05538429: Comparison of Analgesic Effect and Postoperative Recovery of SAPB Combined With ESPB and TPB After Thoracoscopic Surgery |
|
|
| Recruiting | N/A | 92 | RoW | erector spinal plane combined with serratus anterior plane block, thoracic paravertebral block | Zhangyi | Thoracoscopic Surgery, Nerve Block | 10/22 | 11/22 | | |
NCT04503915: Estrogen Supplementation Mode in HRT-FET Cycle: a RCT |
|
|
| Not yet recruiting | N/A | 784 | NA | different estrogen supplementation modes | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Hormone Replacement Therapy, Estrogen, Live Birth Rate | 11/22 | 12/23 | | |
| Recruiting | N/A | 2500 | RoW | | Xuanwu Hospital, Beijing, ChosenMed Technology (Beijing) Co.,Ltd | Non-small Cell Lung Cancer | 11/22 | 11/22 | | |
NCT06375447: Intelligent Diagnosis and Treatment Model for Insomnia Disorder |
|
|
| Recruiting | N/A | 16000 | RoW | Routine clinical treatment | Xuanwu Hospital, Beijing, West China Hospital, Beijing Tiantan Hospital, Second Affiliated Hospital of Soochow University, Chifeng City Center Hospital Ningcheng County | Insomnia | 10/25 | 12/25 | | |
HCF-CMP-AF, NCT04127799: Integrative Management of Patients With Atrial Fibrillation Via Hospital-Community-Family-Based Telemedicine (HCFT-AF) Program |
|
|
| Recruiting | N/A | 1000 | RoW | Hospital-Community-Family-Care Management Platform Online, Subjects with AF conventional treatment | Northern Jiangsu Province People's Hospital | Telemedicine, Atrial Fibrillation | 12/22 | 09/23 | | |
NCT05792865: A Registry Study of Patients Hospitalized With Confirmed COVID-19 |
|
|
| Not yet recruiting | N/A | 488 | NA | paxlovid, paxlovid within initial 5 days, No paxlovid, Paxlovid, Paxlovid outside of the initial 5 days | Beijing Chao Yang Hospital | COVID-19 | 06/23 | 12/23 | | |
| Recruiting | N/A | 10 | RoW | TCR T-cells | Beijing Geekgene Technology Co., LTD | Gastric Cancer, Esophageal Cancer, Cervical Cancer, Non-Small Cell Lung Cancer NSCLC, Triple Negative Breast Cancer TNBC | 07/26 | 11/26 | | |
| Recruiting | N/A | 20 | RoW | JY231 Injection | Shenzhen Genocury Biotech Co., Ltd. | B-NHL, B-ALL | 09/26 | 12/26 | | |
NCT06133725: TAPB Combined With RSB Versus ESPB for Postoperative Analgesia After Laparoscopic Liver Resection |
|
|
| Not yet recruiting | N/A | 60 | RoW | erector spinae plane block, transversus abdominis plane block combined with rectus sheath block | Zhangyi | Laparoscopic Hepatectomy, Nerve Block | 11/24 | 12/24 | | |
NCT06198517: Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT |
|
|
| Recruiting | N/A | 254 | RoW | Moxibustion, Symptomatic treatment | Wuhan Union Hospital, China | Moxibustion, Hematopoietic Stem Cell Transplantation, Hemorrhagic Cystitis, Prevention | 09/25 | 12/25 | | |
| Not yet recruiting | N/A | 20 | NA | Tumor polypeptide pool induced DC-CTL cell injection | Zhengzhou Revo-Gene Technology Co., LTD, The First Affiliated Hospital of Zhengzhou University | Solid Tumor | 04/26 | 04/26 | | |
NCT06241274: Moxibustion in the Treatment of Hemorrhagic Cystitis After Allo-HSCT |
|
|
| Recruiting | N/A | 60 | RoW | Moxibustion, Symptomatic supportive treatment | Wuhan Union Hospital, China | Moxibustion, Hematopoietic Stem Cell Transplantation, Hemorrhagic Cystitis, Treatment | 09/25 | 12/25 | | |
NCT03845088: Application of Virtual Mandibular Position in Temporomandibular Jont Reconstruction With Costochondral Graft in Children Jaw Deformity |
|
|
| Recruiting | N/A | 15 | RoW | temporomandibular jont reconstruction with costochondral transplantation | Peking University | Temporomandibular Joint Ankylosis, Facial Asymmetry | 09/24 | 12/24 | | |
NCT06607926: Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC |
|
|
| Not yet recruiting | N/A | 40 | RoW | Thymosin Alpha 1, thymalfasin, Tislelizumab, Platinum-doublet chemotherapy | Xuanwu Hospital, Beijing | Resectable Non-Small-Cell Lung Cancer | 06/25 | 12/25 | | |
NCT03908671: Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Cancer and Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 24 | RoW | Personalized mRNA Tumor Vaccine | Stemirna Therapeutics, The First Affiliated Hospital of Zhengzhou University | Esophageal Cancer, Non Small Cell Lung Cancer | 10/24 | 12/25 | | |
| Completed | N/A | 55 | US | Experimental: Locomotor Learning | VA Office of Research and Development | Aging | 06/24 | 06/24 | | |
NCT05478759: Innovative Multimodal and Attention Training to Improve Emotion Communication in Veterans With TBI and PTSD |
|
|
| Recruiting | N/A | 20 | US | Multimodal affect recognition training, MMART, Attention Training, Brain HQ, Brain Health Workshop, BHW, National Geographic Movies, movies | VA Office of Research and Development | Brain Injury, Post Traumatic Stress Disorder | 11/25 | 12/25 | | |
NCT06658951: Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors |
|
|
| Not yet recruiting | N/A | 30 | RoW | Anti-HER2 CAR-T cells | UTC Therapeutics Inc., The First Affiliated Hospital of Zhengzhou University | HER2-positive Advanced Malignant Solid Tumors | 11/26 | 11/27 | | |
NCT05308875: Efficacy and Safety Evaluation of PD1-BCMA-CART |
|
|
| Not yet recruiting | N/A | 9 | RoW | PD1-BCMA-CART | Bioray Laboratories, The First Affiliated Hospital of Zhengzhou University | Multiple Myeloma | 01/25 | 10/25 | | |
| Recruiting | N/A | 1114 | RoW | TaTME, Transanal TME, LpTME, Laparoscopic TME | Sun Yat-sen University, Peking Union Medical College Hospital, The First Hospital of Jilin University, RenJi Hospital, Shengjing Hospital, The Second People's Hospital of Yibin, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Nanchong Central Hospital, Zunyi Medical College, The First Affiliated Hospital of University of South China, Xinqiao Hospital, Nanfang Hospital, Southern Medical University, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, Affiliated Hospital of Guangdong Medical University, The Third Xiangya Hospital of Central South University | Rectal Neoplasms Malignant, Surgery | 07/26 | 07/26 | | |
| Recruiting | N/A | 1000 | US | MicroVention Mechanical Thrombectomy Devices as first-line treatment | Microvention-Terumo, Inc. | Acute Ischemic Stroke, Vessel Occlusion, Stroke, Ischemic | 12/25 | 12/25 | | |
NCT05380050: Comparing Telehealth to In-person a Combined Metacognitive Training in Veterans With mTBI/PTSD |
|
|
| Recruiting | N/A | 63 | US | Goal Management Training plus Attention Training, GMT + ATT, Brain Health Workshop and National Geographic Movies, BHW and National Geographic Movies | VA Office of Research and Development | Brain Injury, Cognition, PTSD, Intervention | 10/26 | 10/26 | | |
NCT05409989: MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study |
|
|
| Recruiting | N/A | 154 | US | FRED™ X™, Flow Re-Direction Endoluminal Device X | Microvention-Terumo, Inc. | Intracranial Aneurysm | 09/29 | 11/29 | | |
MCBDTMIDT, NCT04817748: Metabolomics Characterization of Biomarkers of Different Types of Myocardial Infarction in Different Time. |
|
|
| Recruiting | N/A | 40 | RoW | | Shanghai 10th People's Hospital | Myocardial Infarction | 05/21 | 05/21 | | |
NCT05146063: LNK in Polycystic Ovary Syndrome With Insulin Resistance |
|
|
| Recruiting | N/A | 80 | RoW | Take the patient's subcutaneous fat tissue to detect the expression of LNK | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Polycystic Ovarian Syndrome, Insulin Resistance | 12/22 | 12/23 | | |
NCT04830826: A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China |
|
|
| Recruiting | N/A | 2000 | RoW | Surgeries | The First Affiliated Hospital of Guangzhou Medical University | NSCLC, Stage I, NSCLC, Stage II, NSCLC, Stage III | 01/24 | 07/24 | | |
NCT05593081: Multicenter Study of Fulminant Type 1 Diabetes in China |
|
|
| Recruiting | N/A | 240 | RoW | HLA | Second Xiangya Hospital of Central South University | Diabetes Mellitus, Type 1 | 12/27 | 12/27 | | |
NCT05435898: Assessment and Digital-health Based Intervention on Subclinical Organ Damage and Cardiovascular Risk in Chinese |
|
|
| Not yet recruiting | N/A | 4000 | RoW | | Shanghai 10th People's Hospital | Cardiovascular Diseases, Cardiovascular Morbidity, Subclinical Organ Damage, Digital Health | 09/29 | 09/29 | | |
| Xu, Gang |
NCT06528015: Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy |
|
|
| Not yet recruiting | 4 | 206 | RoW | probiotics combined with enteric-coated budesonide capsule, probiotics placebo combined with enteric-coated budesonide capsules | Gang Xu, China Primary Health Care Foundation | Glomerulonephritis, IGA, Probiotics, Budesonide | 12/26 | 12/28 | | |
NCT04381143: ASPIrin in Reducing Events in Dialysis ( ASPIRED ) |
|
|
| Recruiting | 4 | 9000 | RoW | Aspirin 100 mg Oral Tablet, Matching Placebo | Guangdong Provincial People's Hospital, The George Institute | CKD (Chronic Kidney Disease) Stage 5D | 09/26 | 12/26 | | |
| Suspended | 2 | 279 | Europe, US, RoW | zetomipzomib, KZR-616, placebo, matching placebo | Kezar Life Sciences, Inc. | Lupus Nephritis | 05/26 | 07/26 | | |
NCT05512988: Human Umbilical Cord Mesenchymal Stem Cell(UC-MSC)Delayed Renal Chronic Kidney Disease(CKD3、4 ) |
|
|
| Recruiting | 1/2 | 44 | RoW | UC-MSC, Saline solution | Tongji Hospital, Zhongyuan Xiehe Biological Cell Storage Service (Tianjin) Co., Ltd. | Chronic Kidney Diseases | 04/24 | 05/24 | | |
| Recruiting | N/A | 80 | RoW | Fluroquinolones, levoflocaxin (Cravit), moxifloxacin (Avelox), ciprofloxacin (Cifran), Beta-lactamase inhibitor, amoxicillin clavulanate potassium compound (Junerqing) | Guangzhou Institute of Respiratory Disease | Bronchiectasis | 12/23 | 12/23 | | |
| Recruiting | N/A | 366 | Canada, RoW | | The George Institute, Peking University Institute of Nephrology | IgA Nephropathy, ESRD, Glomerulonephritis, Kidney Diseases | 07/27 | 07/27 | | |
| Davis, Steven A |
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color |
|
|
| Active, not recruiting | 3 | 80 | US | Lebrikizumab, LY3650150, DRM06 | Eli Lilly and Company | Atopic Dermatitis | 05/24 | 02/25 | | |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight |
|
|
| Recruiting | 3 | 250 | US | Ixekizumab, LY2439821, Tirzepatide, LY3298176 | Eli Lilly and Company | Psoriasis, Obesity | 12/25 | 05/26 | | |
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period |
|
|
| Active, not recruiting | 3 | 1108 | Europe, Canada, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 12/24 | 11/25 | | |
NCT06163404: Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant |
|
|
| Recruiting | N/A | 50 | US | Implantation of Spirair Nasal Device using the Spirair delivery system., SeptAlign | Spirair, Inc | Nasal Septal Deviation, Nasal Airway Obstruction | 12/24 | 07/25 | | |
NCT06477172: Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures |
|
|
| Recruiting | N/A | 500 | Canada, US | | Acorn Biolabs Inc. | Post Procedural Erythema | 02/25 | 02/25 | | |
| Yuan, Xianglin |
| Recruiting | 4 | 40 | RoW | Hetrombopag Olamine | Huazhong University of Science and Technology | Malignant Tumors of the Digestive System, Trombocitopenia | 10/23 | 12/23 | | |
NCT03236649: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects |
|
|
| Terminated | 3 | 89 | RoW | Icaritin, Sorafenib Tosylate Tablets | Beijing Shenogen Biomedical Co., Ltd, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Eastern Theater General Hospital,QinHuai District Medical Area, Peking University Cancer Hospital & Institute, Chinese PLA General Hospital, Beijing Hospital, General Hospital of Chinese Armed Police Forces, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, The Fourth Hospital of Hebei Medical University, Hunan Cancer Hospital, The First Hospital of Jilin University, 307 Hospital of PLA, Fudan University, Henan Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital of Soochow University, Tongji Hospital, Beijing YouAn Hospital | Hepatocellular Carcinoma (HCC) | 02/22 | 02/22 | | |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
GAPSO, NCT03801668: Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma |
|
|
| Recruiting | 3 | 294 | RoW | Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1 | Huazhong University of Science and Technology, CSPC Ouyi Pharmaceutical Co., Ltd. | Gastric Cancer | 12/22 | 03/23 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
NCT05918094: Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 3 | 540 | RoW | Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab | Sun Yat-sen University | Gastric Cancer | 12/26 | 12/28 | | |
NCT05687357: Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma |
|
|
| Recruiting | 2b | 140 | RoW | Tislelizumab, S-1, Oxaliplatin, Nab paclitaxel, Radiation | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Gastric Cancer, Gastroesophageal-junction Cancer | 02/27 | 08/27 | | |
NCT04603040: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers |
|
|
| Recruiting | 2 | 100 | RoW | Toripalimab, Tuoyi | Shanghai Junshi Bioscience Co., Ltd. | Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy | 12/22 | 03/23 | | |
NCT05438108: SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC |
|
|
| Recruiting | 2 | 30 | RoW | SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab | Huazhong University of Science and Technology | Metastatic Colorectal Cancer | 01/23 | 01/24 | | |
NCT04294784: Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer |
|
|
| Terminated | 2 | 58 | RoW | Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor), Albumin-bound Paclitaxel | Huazhong University of Science and Technology | Gastric Cancer, GastroEsophageal Cancer | 11/23 | 11/23 | | |
NCT06168786: Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC |
|
|
| Recruiting | 2 | 40 | RoW | Fruquintinib, Cadonilimab, SBRT | Huazhong University of Science and Technology | Colorectal Cancer | 02/26 | 02/27 | | |
NCT06516445: SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC |
|
|
| Recruiting | 2 | 33 | RoW | SCRT, Camrelizumab, Fluzoparib, CAPEOX | Huazhong University of Science and Technology | Colorectal Cancer | 06/25 | 06/26 | | |
NCT06199895: Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer |
|
|
| Recruiting | 2 | 25 | RoW | Paclitaxel Polymeric Micelles for Injection | Liu Huang | Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Stomach Cancer, Esophageal Carcinoma, Breast Cancer | 11/25 | 11/25 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study |
|
|
| Recruiting | 2 | 276 | RoW | LM302+Toripalimab, LM302+JS001 | LaNova Medicines Zhejiang Co., Ltd. | Gastric Cancer, Pancreatic Cancer | 07/25 | 01/26 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT06592287: The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer |
|
|
| Not yet recruiting | 1/2 | 66 | RoW | Adebrelimab + Apatinib + Lrinotecan liposome | Xianglin Yuan | Advanced Gastric Cancer | 09/25 | 09/26 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
NCT02490319: Study on the Biological Prediction Models of Radiation Pneumonitis |
|
|
| Recruiting | N/A | 300 | RoW | | Huazhong University of Science and Technology | Radiation Pneumonitis | 07/23 | | | |
NCT06551207: Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC |
|
|
| Recruiting | N/A | 80 | RoW | Fruquintinib, Cadonilimab, SBRT | Liu Huang | Metastatic Colorectal Cancer | 12/26 | 12/27 | | |
